Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development

Recently, the '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor,' jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on the Bund.
Amid the global trend of industrial innovation, the results of the '2025 Pioneer Innovators in Industry Development' selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. Dr. Yuxin Chen, with a strong academic background and solid capabilities inconvertingacademic research into industrial applications, successfully led the global R&D and clinical development of multiple first-in-class (FIC) innovative drugs. The core products of ProteLight Pharmaceuticals, founded by Dr. Chen, have entered pivotal clinical trials in both China and the United States. They demonstrate outstanding original R&D capabilities and a forward-looking international development strategy. Dr. Chen was named a 2025 Forbes China Pioneer Innovator in Industry Development.
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.,
[Honored as a 2025 Forbes China Pioneer Innovators in Industry Development]
Dr. Wang Xin, Global Partner and President of Sullivan Greater China, together with Professor Yu Wang, Expert Advisor to the Judging Committee and Chairman of Chinese Foundation for Hepatitis Prevention and Control, presented the award to Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
China's Pioneer in Antimicrobial Peptide Innovation: ProteLight Pharma's Peceleganan Ushers in a New Era of Anti-Infective Therapy
ProteLight Pharma has achieved a historic breakthrough in China's innovative drug development with its independently developed antimicrobial peptide spray Peceleganan (PL-5). It is the first antimicrobial peptide innovative drug in China to enter clinical trials and submit a New Drug Application (NDA), and it has also advanced to Phase II clinical trials in the United States. In addition, it has been granted the WHO International Nonproprietary Name (INN) 'Peceleganan,' marking the first time a Chinese-developed antimicrobial peptide compound has obtained an international nonproprietary name. Dr. Yuxin Chen, founder of ProteLight Pharma, proposed the revolutionary 'Membrane Discrimination Mechanism,' which fundamentally addresses the problem of antimicrobial resistance. In clinical trials, the Peceleganan spray demonstrated broad-spectrum efficacy, high potency, and a low potential for resistance. This breakthrough innovation received the 'Peptide Application Special Award' at the 15th Chinese International Peptide Symposium. Based on this original mechanism, ProteLight Pharma has established a world-leading rational design platform for antimicrobial peptide drug development, along with an advanced formulation R&D platform for peptide drugs, laying a solid foundation for the future growth of its product pipelines.
A Full Value Chain Creator: An Outstanding Model of R&D Breakthroughs and Commercialization
ProteLight Pharma has signed an exclusive cooperation agreement with China's pharmaceutical giant Chia Tai Tianqing, which is responsible for the full-scale commercialization of the PL-5 spray in the Chinese market. The company is now valued at over 2 billion RMB and has secured more than 60 million RMB in funding from the national '12th Five-Year Plan' and '13th Five-Year Plan' Major New Drug Innovation Programs, as well as from provincial and municipal science and technology funds. Notably, PL-5 has demonstrated significantly better clinical efficacy than traditional antibiotics in treating difficult-to-heal infected wounds such as diabetic foot ulcers and extensive burns. It has consistently met primary endpoints across all phases of clinical trials, providing a Chinese solution to the global problem of drug-resistant bacterial infections. In addition to anti-infective therapies, ProteLight Pharma is also expanding into oncology, autoimmune diseases, and metabolic disorders. The company has already developed several preclinical-stage innovative drug candidates in these areas.
China's Strength in the Global Battle Against Antimicrobial Resistant Bacteria: Building a Sustainable Biopharmaceutical Innovation Engine
Facing the growing global crisis of antibiotic resistance, ProteLight Pharma is seizing the historic opportunity for antimicrobial peptide drug development and has laid out a clear development plan. Peceleganan is expected to obtain its new drug certificate in early 2026, and the follow-up product PL-18 is scheduled to enter Phase III clinical trials in China in the fourth quarter of 2025. The company is currently advancing its Round E financing, with a focus on strengthening its R&D system and expanding its product pipeline. Dr. Yuxin Chen emphasized that ProteLight Pharma will remain committed to continuous innovation based on its original technology platform. Through further development and application of the 'Membrane Discrimination Mechanism,' the company aims to systematically address key technical challenges from drug discovery to industrialization. Committed to tackling global public health challenges, ProteLight Pharma strives to become a global leader in the field of antimicrobial peptides. This strategic positioning reflects the company's strong sense of social responsibility and highlights the ambition and strength of Chinese innovative pharmaceutical companies in global health governance.
About Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
Founded in April 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. is a high-tech biopharmaceutical company focused on the research, development, and production of peptide and small-molecule drugs. The company is based in Jiangyin Hi-Tech Industrial Development Zone, Jiangsu Province, and is recognized as a National High Tech Enterprise. ProteLight Pharma has several subsidiaries, including wholly owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as Jiangsu Putai Pharmaceutical Technology Co., Ltd., ProteLight Medical Holdings (Hong Kong) Co., Ltd., and ProteLight Pharma (Australia) Pty Ltd.
Innovation-driven drug R&D and production is the core strategy of the company. It has built a diversified pipeline of first-in-class peptide and small-molecule innovative drugs, with a focus on anti-infective, oncology, autoimmune, and metabolic diseases. The company holds dozens of patents, including PCT international patents, U.S. and EU patents, Chinese invention patents, utility model patents, and design patents.
Since its founding, ProteLight Pharma has undertaken over 40 scientific research projects, including the national 'Major New Drug Innovation' projects under the 12th and 13th Five-Year Plans, and the 'Funding Program for Preferential Returned Scientific Research Students Innovative and Start-ups.'
The company was selected as one of the first key entrepreneurial teams by the Overseas Chinese Affairs Office and was awarded the 'Outstanding Entrepreneur Award'.
Looking ahead, the company will continue to build on its antimicrobial peptide product foundation, maintaining a balanced focus on R&D and business operations. With high-quality innovative products, ProteLight Pharma aims to become a global leader in the field of antimicrobial peptide pharmaceuticals.
About the 2025 Forbes China Pioneer Innovators in Industry Development Selection
The '2025 Forbes China Pioneer Innovators in Industry Development' selection is jointly organized by Forbes China and Frost & Sullivan. It aims to identify and recognize entrepreneurs who demonstrate innovation and leadership in key areas such as life sciences, industry and energy, AI and information technology, and consumer finance and services. The evaluation process adopts rigorous data analysis and case study methodologies to comprehensively assess candidates' innovation strategies, market influence, and growth potential. This selection not only serves as an authoritative recognition of industry leaders, but also aims to inspire more entrepreneurs to embrace technological innovation and contribute to the sustainable development of their industries.
Media Contact
Company Name: Frost & Sullivan
Contact Person: Qian Li
Email: Send Email
Country: China
Website: http://www.frostchina.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Forbes

30 minutes ago

• Forbes

Silicon Valley's Leadership Lessons

Leadership lessons from Silicon Valley for future readiness Mature organizations lose their vitality. Complex organizations lose their responsiveness. Successful incumbent market leaders, because they are typically both mature and complex, lose their charm, and become endangered. Not surprisingly, there has long been a search for ways to restore vigor and zest to such organizations. Inevitably, when such discussions arise, the success of Silicon Valley is cited as an alternative example of both energy and imagination; of being able to move fast and change things in a big way. The recent DOGE (Department of Government Efficiency) initiative is one such effort. The advertised idea was to learn from the 'new economy,' and apply those lessons learned to large, bureaucratic, government agencies. That this does not appear to have happened is probably due more to chaotic execution and the mischief of ideologues than to a failure in the promise of Silicon Valley as an organizing inspiration for the rest of us. Not entirely coincidentally, the UK's Advanced Research and Invention Agency (ARIA) is another example. Inspired, in part, by the American Defense Advanced Projects Research Agency (DARPA), which, established in 1958 in response to the Soviet Union's Sputnik, has continually played an influential role in Silicon Valley successes, ARIA's American born Ilan Gur sees his organization as a means of supporting UK innovation, which he refers to as a 'tightly wound spring that's ready to release'. What is it, then, about Silicon Valley that leads it to be seen as a source of managerial lessons for organizational success, and what might those lessons be? To answer these questions, I took the opportunity to interview an old friend and IMD colleague, Jim Pulcrano, engineer, entrepreneur, academic, and who for over 25 years has been an observer of Silicon Valley's inner workings, leading more than 80 executive explorations of the Valley in search of such lessons. What follows is a sense of what leadership lessons Silicon Valley might offer those of us who work in mature, old-economy, industries, and especially those of us associated with successful, incumbent, market-leaders, in such industries: Thinking Differently Jim Pulcrano: I think that the Silicon Valley lessons all begin with one word: '"urgency." Mature firms often become comfortable—they've grown strong, built moats, have big balance sheets. But that comfort is a trap. Silicon Valley thrives on discomfort. Everyone there is asking, 'What's next?' and 'How fast can I disrupt myself before someone else does?' Bill Fischer: And how does that urgency manifest itself? Pulcrano: Through relentless questioning. The best innovators don't start with answers—they start with better questions. What if we made a 10X improvement, not 10%? What if we killed our core product before someone else did? What if our future doesn't look like our past? Fischer: This is a dramatically different way of thinking than we typically see in more traditional organizations. Pulcrano: Revitalization requires daring and courage. Mature companies often cling to what worked in the past; the leaders usually built their legacies on products and systems that have outlived their utility and should be disrupted. In contrast, Silicon Valley is all about 'dream big or stay home.' It teaches us that innovation isn't about fine-tuning yesterday's model—it's about asking bold, even uncomfortable, questions. That culture of relentless curiosity that we hear about so often; it's gold. Fischer: So, it's about more than simply having a flashy R&D team? Pulcrano: Exactly. You need a network that nourishes innovation—not just exploits it. One important lesson is that in the Valley geographic proximity makes a difference. Everything is tightly packed together: venture capital, prototyping labs, universities, and legal experts. Ideas bounce around fast. That 'proximity stew' keeps innovation alive. For incumbents, the question becomes: how do we recreate that bubbling ecosystem internally? In a mature company, you've got to mimic that intensity. Create idea collisions. Flatten silos. Interest engineers in talking to marketers, finance to R&D. In Silicon Valley, the network is the superpower. People move freely—from startup to corporate, from VC to academia, then back. The real learning happens in the spaces between. Incumbents need to stop thinking in organizational charts and start thinking in ecosystems. Who do your innovators know outside your organization? What cross-pollination is happening? Who is the go-to person on X? Are you one of them? Leadership lessons Fischer: how different is the practice of leadership in such organizations? Pulcrano: First, leaders must normalize failure. In the Valley, failing fast and moving on is a badge of honor. Max Levchin, Elon Musk's Paypal cofounder, struggled with his first four startups struggled (and mostly failed). The fifth was PayPal. Most legacy firms? They'd have fired him after the second flop. Fischer: Failure becomes data? Pulcrano: Exactly. In the Valley, failure isn't the opposite of success—it's part of the process. That's a cultural shift. Leaders must model that by sharing their own missteps. Celebrate intelligent risk-taking, not just polished outcomes. Nobody wants to fail, it's f**king awful, but if you're trying to do something new, whether it be the technology, the business model or some combination, failure is likely, so learn from it. Second, diverse thinking isn't a bonus—it's a baseline. The best decisions in VC firms often come after heated debates. The VC firm Greylock Partners has even studied this—their biggest wins were investments that triggered the fiercest internal arguments. So if your executive team always agrees, you're in trouble. Fischer: That's quite a departure from many boardrooms; it reminds me of the adage: 'polite teams get polite results.' Pulcrano: It is. And that leads to another principle: permissionless innovation. In the Valley, junior people prototype without asking for five layers of approval. Those prototypes could be products or sales models. Leaders should ask themselves: "Am I enabling action, or am I an obstacle?" Fischer: What does that look like in practice? Pulcrano: One example is Google X. When a moonshot project failed—after years and millions invested—the team that shut it down got a bonus. Why? Because they made the right call. They stopped something that wasn't going to work and freed resources for better bets. Does Culture Really Eat Strategy for Breakfast? Fischer: Peter Drucker famously told us that 'culture eats strategy for breakfast,' so I'm interested in what you think about organizational culture, and how important it is for success in Silicon Valley? Pulcrano: A few things about culture: First: optimism. Even when Silicon Valley Bank [SVB] collapsed, in 2023, the Valley shrugged and poured money into AI startups the next week. That attitude? 'What if it works?'—it's infectious. Second: role models. Everyone in the Valley knows someone who built something, or at least tried. That proximity to success makes ambition feel doable. Third: constructive promiscuity. At a typical Valley barbecue, people swap business cards before burgers. It's not impolite—it's expected. Fischer: Am I right in thinking that the way you see it in Silicon Valley is that a lot of culture is tactical? Pulcrano: In the Valley, it's curiosity and opportunity rolled together. Everyone is 'on the make' always, but everyone is also looking to help, invest, and collaborate. That ethos is powerful. But it can fade—especially as wealth accumulates, risk aversion creeps in, and firms become protectionist. What does the Future of Silicon Valley Look Like? Fischer: I'm in interested in how durable these lessons might be? Silicon Valley has dominated for over fifty years. But can it continue? What might the next fifty look like? Pulcrano: That's a provocative question. I'm optimistic, but cautiously so. Silicon Valley's strength has always been reinvention. Semiconductors, personal computing, the internet, biotech, social media, AI—wave after wave. Each time, it adapted. But now? Fischer: You're not convinced? Pulcrano: I'm seeing signs of incumbent behavior. Some of the giants—Google, Meta, Apple—are acting like the very firms they once disrupted. Risk-averse. Bureaucratic. More lawyers than engineers. That's worrying. Fischer: So, what would it take to stay relevant? Pulcrano: It needs fresh blood. And that's under threat. Immigration policies, visa restrictions—they're slowing down the global talent pipeline. Remember, 60% of the Valley's tech workforce isn't U.S.-born. Choke that off, and the Valley stops breathing. Fischer: So, the magic is in the mix? Pulcrano: Always has been. People come not just from Harvard and MIT, but from India, China, Nigeria, Slovenia. They bring their ambitions, the chips on their shoulders. That stew of dreams and hunger—that's Silicon Valley's secret sauce. Fischer: Can other regions replicate the magic of Silicon Valley? Pulcrano: Not exactly, but they can recreate parts of it. You need three ingredients: talent, money, and ideas, and they must come together efficiently. But it's the efficiency with which you mix them that makes the difference. Fischer: That efficiency being? Pulcrano: Access. In the Valley, the customer, the VC, the tech shop, the legal expert—they're all accessible within 30 minutes. You pitch an idea at breakfast, and prototype it by dinner. That's hard to reproduce in sprawling ecosystems or hierarchical, process-driven multinationals. Fischer: How can incumbents inside large firms imitate that? Pulcrano: Start small. Create internal innovation hubs where people are free to experiment. Kill bureaucracy. Protect intrapreneurs. Build a real network of mentors. Most importantly, ensure sharing and success are incentivized. If ideas stay locked in departments, or behind IP walls, you've already lost. Final Thoughts Fischer: This has all been very interesting! If you could leave our readers with one challenge—especially leaders in mature firms—what would it be? Pulcrano: Ask yourself: 'Am I creating a space where innovation is possible, or merely tolerated?' Then look around. If your team is afraid to disagree, if failure is punished, if new ideas die in PowerPoint—your culture needs rewiring. And, if you are wondering whether you need to go to California to do this: you don't. The Valley isn't a place—it's a mindset. You just need to think like a rebel—and surround yourself with others who will, too.

Yahoo

33 minutes ago

• Yahoo

Top economist who previously sounded the alarm on tariffs sees a possible scenario where Trump ‘outsmarted all of us'

Torsten Sløk, chief economist at Apollo Global Management, laid out a potential scenario where President Donald Trump's tariffs are extended long enough to ease economic uncertainty while also providing a significant bump to federal revenue. That comes as the 90-day pause on Trump's 'reciprocal tariffs' is nearing an end. Businesses and consumers remain in limbo over what will happen next with President Donald Trump's tariffs, but a top economist sees a way to leave them in place and still deliver a 'victory for the world.' In a note on Saturday titled 'Has Trump Outsmarted Everyone on Tariffs?', Apollo Global Management Chief Economist Torsten Sløk laid out a scenario that keeps tariffs well below Trump's most aggressive rates long enough to ease uncertainty and avoid the economic harm that comes with it. 'Maybe the strategy is to maintain 30% tariffs on China and 10% tariffs on all other countries and then give all countries 12 months to lower non-tariff barriers and open up their economies to trade,' he speculated. That comes as the 90-day pause on Trump's 'reciprocal tariffs,' which triggered a massive selloff on global markets in April, is nearing an end early next month. The temporary reprieve was meant to give the U.S. and its trade partners time to negotiate deals. But aside from an agreement with the U.K. and another short-term deal with China to step back from prohibitively high tariffs, few others have been announced. Meanwhile, negotiations are ongoing with other top trading partners. Trump administration officials have been saying for weeks that the U.S. is close to reaching deals. On Saturday, Sløk said extending the deadline one year would give other countries and U.S. businesses more time to adjust to a 'new world with permanently higher tariffs.' An extension would also immediately reduce uncertainty, giving a boost to business planning, employment, and financial markets. 'This would seem like a victory for the world and yet would produce $400 billion of annual revenue for US taxpayers,' he added. 'Trade partners will be happy with only 10% tariffs and US tax revenue will go up. Maybe the administration has outsmarted all of us.' Sløk's speculation is notable as he previously sounded the alarm on Trump's tariffs. In April, he warned tariffs have the potential to trigger a recession by this summer. Also in April, before the U.S. and China reached a deal to temporarily halt triple-digit tariffs, he said the trade war between the two countries would pummel American small businesses. More certainty on tariffs would give the Federal Reserve a clearer view on inflation as well. For now, most policymakers are in wait-and-see mode, as tariffs are expected to have stagflationary effects. But a split has emerged. Fed Governor Christopher Waller said Friday that economic data could justify lower interest rates as early as next month, expecting only a one-off impact from tariffs. But San Francisco Fed President Mary Daly also said Friday a rate cut in the fall looks more appropriate, rather than a cut in July. Still, Sløk isn't alone in wondering whether Trump's tariffs may not be as harmful to the economy and financial markets as feared. Chris Harvey, Wells Fargo Securities' head of equity strategy, expects tariffs to settle in the 10%-12% range, low enough to have a minimal impact, and sees the S&P 500 soaring to 7,007, making him Wall Street's biggest bull. He added that it's still necessary to make progress on trade and reach deals with big economies like India, Japan and the EU. That way, markets can focus on next year, rather near-term tariff impacts. 'Then you can start to extrapolate out,' he told CNBC last month. 'Then the market starts looking through things. They start looking through any sort of economic slowdown or weakness, and then we start looking to '26 not at '25.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

2 hours ago

• Yahoo

Tesla (NasdaqGS:TSLA) Set To Enter Indian Market With First Showrooms In July

Tesla is set to make a significant shift, entering the Indian market in July 2025 with new showrooms. This expansion comes at a time when the company's stock price rose by 30% over the last quarter, amid flat market performance in the past week and a 10% rise over the past year. The entry into India is aimed at countering declining sales in Europe and China, which could have influenced investor sentiment. Despite challenges such as a recent lawsuit and executive changes, this regional expansion might add weight to the broader market uptrend. Tesla has 2 risks we think you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent announcement of Tesla's expansion into the Indian market is a significant development that could influence its broader growth narrative. Despite facing challenges in other regions, this move may provide a new revenue stream, potentially mitigating some of the pressures from decreasing sales in Europe and China. Over the past five years, Tesla's shares have seen a very large total return of 403.51%, illustrating substantial long-term growth. When comparing to the previous year, Tesla's share return also surpassed the market, which returned 10%, and the US Auto industry, which posted a 60.9% gain over the past year. This suggests persistent investor confidence in Tesla, supporting its trajectory even amid short-term volatility. The strategic entry into a new market such as India might bolster revenue and earnings forecasts, as analysts anticipate a 16.6% annual revenue growth over the next three years. However, potential risks including geopolitical uncertainties and leadership changes could impact execution. With Tesla's current share price at US$275.35, it is trading close to the analyst consensus price target of US$289.44, suggesting a modest upside of 4.9%. This share price movement reflects mixed sentiments among investors regarding the balance of growth potential and inherent risks. Tesla's diverse initiatives, ranging from autonomous vehicles to energy solutions, underline its pursuit of long-term profitability, suggesting a complex interplay of factors influencing its market position. Gain insights into Tesla's outlook and expected performance with our report on the company's earnings estimates. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:TSLA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Connectez-vous pour accéder à votre portefeuille